Lv5
820 积分 2024-02-13 加入
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
12小时前
已完结
Models of hyperglycaemia in diabetes mellitus and its complications
2个月前
已完结
The gut microbiome and ageing trajectories: mechanisms and clinical implications
2个月前
已完结
Blood-based obesity biomarkers and their relevance for disease risk
2个月前
已完结
Body composition by DXA
2个月前
已完结
Development and clinical application of bioelectrical impedance analysis method for body composition assessment
2个月前
已完结
Clinical obesity in Asian people: bridging the gap between adiposity and disease
2个月前
已完结
Advances in diagnosing and treating diabetic retinopathy
2个月前
已完结
Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis
3个月前
已完结
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
